, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 15 | 16 ||

- ...

-- [ 17 ] --

, , - , , , . , . . , .

.

/ 20032009 . 2124 , 574 HBsAg -HCV.

, , , : 56,9% -HCV, 21,2% HBsAg. , , () 90,61,8% 28,22,7% (=0,01).

- , (21,92,6%) , (21,82,5%), . , , 2049 (98%). (66,92,6%) (44,03,1%), (24,12,4%) (17,62,4%). / . .

.

, . , 20122016 . , , 04.09. .., ..

, , () , , 3,5 . , (, , , ). , 70 % . , .

. , , . , , , ( ), - .

.

37 ( 3512 ) . 3 24 , 6 15 . IOTest (Beckman Coulter, USA) (PAS, Partec). Staphylococcus aureus ( ) ( Staphylococcus aureus -). , , G (- Architec C8000) ( ) .

( ), ( /) ( ) . C , . 26 .

. 0,05.

CD3+CD4+- CD4+/CD8+ (=0,001;

=0,0002). (-) 2,6 (p=0,0001) (p=0,0001) ( ). .

, , : (=0,03;

=0,003 ), / (=0,005 =0,00004). : , (p=0,003, p=0,001 p=0,004).

CD3+CD8+ (r=-0,81;

=0,02), - CD4+/CD8+ (r=0,79;

=0,036), - Ig (r=0,89;

=0,018).

, , .

04.09. THE RESULT OF THE IMPLEMENTATION EPIDEMIOLOGICAL SURVEILLANCE SYSTEM AND CONTROL AND RESPONSE MEASURES TU INFLUENZA, ACUTE VIRAL RESPIRATORY INFECTIONS (ARI) AND SEVERE ACUTE RESPIRATORY INFECTION (SARI) Spnu C., Scofera P., Cojocaru R., Eder V., Spnu I., Guriev V., Gheorgita S.

National Center for Public Health, Chisinau, Republic of Moldova The health system of the Republic of Moldova has a nominated infections surveillance system, developed with the support of the World Bank and adjusted to the requirements of WHO, ECDC and CDC, which is connected to the European network EuroFlu and global FluNet WHO influenza surveillance, ARI and SARI. This system includes the National Influenza Center accredited by WHO, a biosafety level BSL 2 and BSL-2 +, with modern equipment, supplies and qualified personnel able to perform the techniques of classical virology and molecular biology. Exploring the epidemiological surveillance system for influenza during 2012 (week 40) 2013 (week 12) made it possible to highlight: extensive spreading, medium intensity 12,770/0000, apogee at week 08/2013, the trend of increas and discreas respectively 2.8 0/ and 2,24 0/0000 Influenza morbidity was included within weeks 04/201312/2013, identified viruses: A (H1N1) pdm, A (H3N2) and B dominant strain A ( H1N1)pdm (51.44%), the rate of positive samples during apogee, increas and discreas, was 48.8, 58.5 and 47.7% respectively, were mostly affected person aged 1564 years (63.2%) and children 014 years (32.0%). Categories of pregnant women and patients with immunocompromised status with confirmed influenza were 22.1% and 22.5%, respectively. ARI morbidity in apogee period was 468,60/0000 and reached epidemic threshold 189,70/0000 and by SARI 76,6 0/ increased compared to the same period of last season 48,30/0000. Control and response measures:

making epidemiological surveillance based on specific and nonspecific indicators allowed to vaccinate about 100 000 at-risk population, predict in real time the evolution of influenza morbidity, health system impact assessment, then appreciated as moderate, confirm clinical biodiagnostical influenza, arguing the need for initiation of therapy avoid severe postinfluenza complications, appreciating that Oseltamivir and Zanamivir sensitive influenza virus strains identified, demonstrating isolated strains belonging and place global phylogenetic tree and argue the need to extend the at-risk population for immunization with vaccine recommended by WHO for the season 20132014.

04.09. .. .. .. .. 36, .. .. .. 106, .. .. .. 240, 270, .. .. .. 12, 65, 114, 123, .. 3, 147, .. 273 .. .. 21 .. 42, .. 165 .. 36, 44, 352, .. 82 .. .. 290, 311 .. .. .. .. 49, 165 .. 36, 44, .. 245 .. .. 141 .. .. 61 .. 12, 65, 114, .. 296 .. .. 141 .. 204, 302, .. 121 .. .. .. .. .. .. .. .. .. .. .. 12, 65, 114, .. .. .. .. .. .. 147, .. .. 49, 52, 80, 82, 87, 92, 165, .. .. .. 302 .. .. 24 .. .. 78 .. .. 311 .. .. .. 24, 29, 33 .. .. 36, 44, 352, 353 .. A.C. 122, 251, 265 .. 78, .. 300 .. .. 216 .. .. 314 .. .. .. .. 134 .. .. .. 237 .. .. 65, 114 .. .. 21 .. 175, .. 175, 181 .. .. 170, 175, 181 .. .. 152 .. .. .. 52 .. 306 .. 144, 230, 237, .. 311 .. .. .. 230 .. 78, .. 65 .. .. 265, 311 .. .. 24 .. .. 54, 56 .. .. 279 .. 3, .. 29 .. .. 230 .. 233, .. 245 .. .. 314 .. .. 21, .. 12, 65, 114, .. 118, .. 290, .. .. .. .. .. .. .. .. .. .. .. .. 240, .. .. .. 152, .. 320, .. .. 141, .. 71, 78, .. .. 49, 52, 80, 82, .. 87, 92, 165, 249, .. 204, .. .. .. .. 52, 80, 82, 87, 92, .. 54, .. .. .. 92 .. 49, 52, 80, 82, 87, 92, .. 175 .. 204, 302, .. 230 .. 129, 251, .. 61, 213 .. 42, .. 3 .. .. 61, 213 .. .. 265 .. .. 216 .. .. 121 .. .. 255, .. 78, .. .. .. .. .. .. .. .. .. .. .. .. .. 129, 251, 265 C Cojocaru R. .. 193 E .. .. 99, 134, 141, 147, 152,199, Eder V. 226, 240, 270, 320, 328, 336, 348, 353 G . .. 121 Gheorgita S. Guriev V. K .. .. 181 Karapetyan K.J. .. 141 Khachatryan T.V. .. 129, 251 Khanjyan G.J. .. M Melik-Andreasyan G.G. .. .. 65 S Scofera P. Spnu C. .. 87 Spnu I. .. .. 273 T Tkhruni F.N. Tsakanyan A.V. .. .. .. 80, .. .. 129, . .. .. 270, .. ..

1. , , , .

2. 1- . Times New Roman 12 , ( ) 1 , , , 25 .

3. , , , 57 4, 12 .

4. .

5. :

1) ;

2) ;

3) , , .

6. ( ) . ( 10 ) , , . ( 5).

7. : , , , ;

: , , ;

(). ( ), .

8. , , , . .

9. , . , . , . , , , .

, . .

10. (, , , ) , - . . (, ) .

, Excel, , Excel . . , , , , , , . . . .

11. ( 10), ( 25), 7.1.-2003 ,, (: [1] [1, 2]).

12. , , , (100150 ) ( , ). .

13. .

14. (..., , , , , , ).

15. . MS Word (*.DOC, *.RTF). ( , _ .doc).

16. . . , - , , , ( ).

17. .

18. , (, , ) .

19. . . , , .

20. .

21. . .

.

:

, . , 23, . , 220114, : (+375-17) 263 64 68;

237 69 : (+375-17) 267 30 : rrpcem@belriem.by belriem@gmail.com,http://www.belriem.by/ .., .., .., ............................................................ ......... .., ...................................................................................................................... .., .., .., .., ............................................ - - .., .., .., ..................................................... .., .., ........................................................................................... .., ................................................................................................................. .., ................................................................................................................... : . .., .., .., .., .., ........... 20102013 . .., .., .., ............................................................................... . : .., .., .., .., .., ........... 19 20052012 .

.., .., .., .., ......................... 3 .., ., .., .., .., ..... BORDETELLA PERTUSSIS, .., ................................................................................................................. 2012 .

.., ................................................................................................................ - - ........................................................................................................................................... .., .., ......................................................................... - : .., .., .., .., .., .., .., ................................................................... :

............................................................................................................................................. .., .., .., .., .., ....... 2013 2012 .

.., .., .., .., ................... . 20112013 .

.., .., .., .., .., .............................................................................................. , 20112012 .

.., .., .., .., .., .., .., .., .., .., ........ :

, , .., .., .., .., ............................. .., ........................................................................................................................... NEISSERIA MENINGITIDIS .., ............................................................................................................................... 20112012 .

.., .., .., .., ................................ - -1, .., .., .., .......................................................................... .......................................................................................................................................... , ...................................................................... - .., .., .., .., ........................................ .., .., .., .......................................................... .., .C., .., .., .., .., .., ............................................................... 19 ܻ ?


.., .., .., .., .., .......... , , , .., .., .., .., ...................................... C / STAPHYLOCOCCUS .., ..................................................................................................................... .., .., .., .., .., .., .., ........................................................ - - - .., .., ........................................................................................... .., .., .., ., ..................................... .., .., .., .., .., .., ............................................................................................ - - .., .., .................................................................................. , .., .., .., .., .., .......................................................................... - - .., ........................................................................................................... .., .., .., .., .., .., ............................................................ : .., .., .., .., ................................ ............................................................................................................................................ - .., .................................................................................................................... NEISSERIA MENINGITIDIS : , , , Y, W135 29E .., ......................................................................................................................... - .., .., .., ..................................................... EVALUATION OF ANTIBIOTIC RESISTANCE OF HUMAN GUT MICROBIOTA PATHOGENS Melik-Andreasyan G.G.,Tkhruni F.N., Tsakanyan A.V., Karapetyan K.J., Khanjyan G.J.,Khachatryan T.V................................................................................... - .., .., .., ...................................................... -28B .., .., .., .., ............................... - :


........................................................................................................................................... - .., ............................................................................................................................. , .., .. .., .., ................................ ........................................................................................................................................ PSEUDOMONAS AERUGINOSA .., .., ..................................................................................... , .., .., ............................................................................................... MYCOPLASMA GENITALIUM .., .., .., .................................................................... , .., .., .., .., .., .... , .., .., .., .., ...................................... 90 91 GYRA , MYCOBACTERIUM TUBERCULOSIS ............................................................................................................................................... - .., .., .., .., ................................................ .., .., ............................................................................................. - , : - .., .., .., .., .., .., ......................................................... .., .., .., .., .., .., ................................................................................ .., .., ................................................................................... .., ......................................................................................................... .., .................................................................................................................. ............................................................................................... .., ......................................................................................................... .., ..................................................................................................................... BALB/C . TRACHOMATIS ( D) .., .

., ................................................................................... , .., .., ................................................................................................ .., .., ............................................................................... .., ..................................................................................................................... - .., .., .., .., .., .... ENTEROCOCCUSFAECALIS .., .., .., ......................................................... BORRELIA BURGDORFERI .., .., .., .., .................................... .., ,., ............................................................................................ S. AUREUS, CANDIDA ALBICANS STR. PYOGENS, .., ......................................................................................................................... - .., .., ............................................................................................... - CB57/BL, .., .., ................................................................................................... - .., .., .., .............................................................. .., .., ............................................................................... - .., .., .., .., ............................... .......................................................................................................... ɻ .., .., .., .., .., .., ....... .., .., .., .., .................................................. , .., .., .., ..................................................................... .., ............................................................................................................. THE RESULT OF THE IMPLEMENTATION EPIDEMIOLOGICAL SURVEILLANCE SYSTEM AND CONTROL AND RESPONSE MEASURES TU INFLUENZA, ACUTE VIRAL RESPIRATORY INFECTIONS (ARI) AND SEVERE ACUTE RESPIRATORY INFECTION (SARI) Spnu C., Scofera P., Cojocaru R., Eder V., Spnu I., Guriev V., Gheorgita S................................... .................................................................................................................. ................................................................................................................... : .-. , - . , . .. : - . , . .. : .. , .. : .. : .. : .. : .. 23.10.2013.

.-. . 44,64.

105 .

02330/0548510 16.06.2009.

. , 28, 220007, . ./ +375 (17) 216-23- E-mail: med@med.by http://www.med.by

Pages:     | 1 |   ...   | 15 | 16 ||
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .